Major review journals do not break news. They consolidate, sift, and tell you where the field actually stands once the noise has settled. The Nature Reviews Disease Primer series exists for exactly that purpose, and the May 2026 issue includes a comprehensive Primer on post-traumatic stress disorder, written by ten of the most cited researchers in trauma science, led by Kerry Ressler at Harvard, Barbara Rothbaum at Emory, and Ronald Kessler, who has spent his career running the World Mental Health Surveys.
This is not a single finding. It is a map. It tells us, as of mid-2026, what is solid, what is provisional, and what is still open. For anyone trying to make sense of trauma and its treatments, that kind of summary is worth more than yet another single-study headline.
The numbers worth knowing
The Primer puts the worldwide lifetime prevalence of PTSD at roughly four to six percent. That figure sounds modest until you compare it to other psychiatric conditions, and then it is large. In high-exposure groups, the number climbs sharply: up to 25 to 30 percent of combat veterans, refugees, and survivors of sexual assault develop PTSD after the index event. In the United States alone, tens of millions of adults have met the criteria at some point in their lives.
The condition rarely sits by itself. The Primer documents very high comorbidity with major depression, anxiety disorders, and substance use disorders, and notes that PTSD is a leading contributor to suicide deaths. It also raises the risk of cardiovascular and metabolic disease, an association that has been consistently replicated in large cohort studies. Untreated PTSD does not stay in its lane: it reshapes both mental and physical health over decades.
Women are more vulnerable than men, partly because the trauma types that most reliably produce PTSD, such as sexual assault and intimate partner violence, are also the traumas to which women are most exposed. Prior childhood adversity, prior episodes of mental illness, and lower socioeconomic status all increase risk. None of these are surprises, but the Primer documents the effect sizes clearly.
Worried about trauma symptoms?
PTSD itself needs a clinical evaluation and cannot be self-screened, but if you have noticed persistent anxiety, low mood, or sensory overwhelm after a difficult event, our validated screenings for anxiety, depression, and sensory processing can be a useful starting point before you talk to a professional.
See validated screeningsThe biology in brief
The Primer reviews what is now established about PTSD as a brain condition. The amygdala, hippocampus, and prefrontal cortex form the core circuit. The amygdala is over-reactive to threat cues, the prefrontal cortex fails to dampen it, and the hippocampus has trouble contextualizing the memory as past rather than present. This is why intrusive memories feel like the trauma is happening now, not why it should feel that way.
Stress hormones are involved too. The hypothalamic-pituitary-adrenal axis, which governs cortisol release, shows a characteristic pattern of dysregulation in PTSD. The picture is more complicated than high or low cortisol, and the Primer is careful not to oversell any single neuroendocrine marker.
Genetics matter, but in the modern, polygenic sense. A 2024 genome-wide association study identified 95 risk loci for PTSD, each of small effect. No single PTSD gene exists. What exists is a distribution of risk, partly shared with depression and anxiety, that interacts with trauma exposure to produce the disorder in some people and not others. The Primer is direct that this is not deterministic: most people exposed to trauma do not develop PTSD, and resilience is itself an active biological and psychological process.
What actually treats it
This is the section where the Primer is least ambiguous, and the message contradicts a lot of internet noise. Trauma-focused psychotherapies remain the first-line treatments for PTSD. Prolonged exposure, cognitive processing therapy, and EMDR all have robust evidence bases, with response rates that medications struggle to match. Trauma-focused CBT works for children, adolescents, and adults.
Medications are useful adjuncts. SSRIs, with sertraline and paroxetine approved by the FDA for PTSD, and SNRIs reduce symptom burden in a meaningful subset of patients. They are not curative, and the Primer notes that medication alone is generally inferior to evidence-based psychotherapy. Benzodiazepines are explicitly not recommended: they impair the extinction learning that recovery depends on.
Newer approaches are mentioned with appropriate restraint. MDMA-assisted psychotherapy generated significant excitement and a 2024 FDA setback when the Lykos application was rejected on quality and methodology grounds. The Primer treats it as a promising but unsettled area. Ketamine, psilocybin, and other novel agents are in earlier-stage research. The honest summary: there is no shortcut yet, and the established treatments are better than headlines often suggest.
Why this Primer lands now
Reviews of this scope take years to write and reflect a field that has, in this case, been busy. The last decade has produced a pandemic with mass bereavement, multiple large-scale armed conflicts, climate-driven disasters, and a wave of public attention to historical trauma. Trauma exposure in 2026 is not historically low. Demand for evidence-based answers, both clinical and personal, has not been higher.
The Primer also reflects a real shift in how the field talks about trauma. PTSD is no longer framed as a single uniform disorder. The authors discuss subtypes, including the dissociative subtype and the ICD-11 complex PTSD diagnosis for survivors of prolonged or repeated trauma. The clinical implication is meaningful: matching the treatment to the trauma pattern, not just to the diagnostic label.
What this means if you are worried about your own trauma
If you have experienced a serious traumatic event and have ongoing intrusive memories, avoidance, mood changes, or hyperarousal that have lasted more than a month and are affecting your life, the right step is a clinical evaluation. PTSD is treatable, and the treatments work better the earlier they are started. Self-help and self-care matter, but they are not a substitute for trauma-focused therapy with a trained clinician.
If you are not sure, validated screenings for related symptoms such as anxiety, depression, and sensory hyperarousal can be a useful first step before a clinical appointment. They are not diagnostic, but they help frame what to bring to the consultation.
The bottom line
The 2026 Nature Primer on PTSD is not news. It is consolidation. It documents what is true: a common, treatable, biologically grounded disorder with effective therapies that remain under-used. It also documents what is still open: subtypes, novel agents, biomarkers, and the broader genetics. The most useful takeaway is the least dramatic. Trauma is common, PTSD is common after severe trauma, and the treatments that exist actually work for most people who try them, particularly when started early.
If you suspect you or someone close to you may have PTSD, the right next step is a clinical evaluation with a psychiatrist, psychologist, or your GP, not a wait for a new drug or a self-administered protocol.
Selected sources
- Ressler KJ, Rothbaum BO, Schnurr PP, Binder EB, Moreland-Capuia A, Nievergelt CM, Koenen KC, Seedat S, Shalev A, Marmar CR, Kessler RC. Post-traumatic stress disorder. Nature Reviews Disease Primers 12, 27 (2026). DOI: 10.1038/s41572-026-00701-1.
- Nievergelt CM et al. Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of PTSD. Nat Genet 56, 792-808 (2024).
- Kessler RC et al. Trauma and PTSD in the WHO World Mental Health Surveys. Eur J Psychotraumatol 8, 1353383 (2017).
- World Health Organization. Post-Traumatic Stress Disorder fact sheet (2024).